Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-12-31FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride (generic) from Lannett Company, Inc., confirming regulatory approv…
-
CLINICAL_TRIALS trial_result · 2013-12-24Clinical Trial Update: Effectiveness of a Physical Activity Intervention to Prevent Obesity and Improve Academic Performance [NA]
This clinical trial update reports on the effectiveness of a physical activity program to prevent obesity and improve academic performance i…
-
CLINICAL_TRIALS research · 2013-12-20Clinical Trial Update: Explore the Association Between the Emotion Recognition and the Attention Processing Under the Emotional Stimuli in ADHD
This clinical trial update investigates the relationship between emotion recognition and attention processing under emotional stimuli in Att…
-
FDA approval · 2013-12-13FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for a generic methylphenidate hydrochloride CD product by Lannett Company, expanding the availab…
-
FDA approval · 2013-12-13FDA Approved: RITALIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for RITALIN (methylphenidate hydrochloride) submitted by Novartis Pharmaceuticals Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-12-13FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental NDA for methylphenidate from Sandoz Inc.
-
FDA approval · 2013-12-12FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the Methylphenidate Transdermal System from Padagis US LLC. This action expands the product's la…
-
FDA approval · 2013-12-12FDA Approved: CONCERTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for CONCERTA (methylphenidate hydrochloride) submitted by Janssen Pharmaceuticals, Inc.
-
FDA approval · 2013-12-12FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for QUILLIVANT XR (methylphenidate hydrochloride) from NextWave Pharmaceuticals, under NDA 20210…
-
FDA approval · 2013-12-12FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN XR, submitted by Sandoz Inc, indicating an approved modification to the product’s labeli…
-
FDA label_change · 2013-12-12FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
The FDA approved a supplemental application for METHYLIN (methylphenidate hydrochloride) submitted by Shionogi Inc. The approval updates the…
-
FDA approval · 2013-12-12FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN (dexmethylphenidate hydrochloride) submitted by Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2013-12-11Clinical Trial Update: The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD [NA]
A completed clinical trial evaluated whether EPA/DHA omega-3 supplementation improves cognitive control in children with ADHD. The study was…
-
CLINICAL_TRIALS trial_result · 2013-12-09Clinical Trial Update: Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials [Phase 4]
Phase 4 clinical trial evaluating whether brain activity flow patterns from evoked response potentials can diagnose Attention Deficit Hypera…
-
FDA approval · 2013-12-04FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Strattera (atomoxetine hydrochloride) submitted by Eli Lilly and Company.
-
FDA approval · 2013-12-03FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for a four-salt dextroamphetamine/amphetamine product manufactured by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2013-11-28Clinical Trial Update: Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD) [NA]
This entry reports the completion and results posting of a pilot feasibility trial evaluating neurofeedback as a treatment for Attention Def…
-
FDA approval · 2013-11-27FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's generic mixed amphetamine salts product (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetami…
-
FDA approval · 2013-11-21FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved the original ANDA for dexmethylphenidate hydrochloride from Amneal Pharmaceuticals of New York LLC, establishing a generic opti…
-
CLINICAL_TRIALS trial_result · 2013-11-19Clinical Trial Update: Preventing Behavior Problems in Children With ADHD [Phase 2]
This Phase 2 clinical trial update examines strategies to prevent behavior problems in children with ADHD. The status is unknown and no resu…
-
FDA approval · 2013-11-19FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved the original application for dexmethylphenidate hydrochloride as a generic product, expanding availability of this ADHD medicat…
-
FDA approval · 2013-11-19FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a generic dexmethylphenidate hydrochloride product from Teva under an original application for the treatment of attention-d…
-
FDA approval · 2013-11-18FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Original Application (Par Health USA, LLC)
FDA approved the original application for a generic dexmethylphenidate hydrochloride extended-release product from Par Health USA, LLC, for …
-
CLINICAL_TRIALS trial_result · 2013-10-31Clinical Trial Update: Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder [Phase 4]
Phase 4 clinical trial update describing medication strategies for reducing aggressive behavior in youths with ADHD. The study includes chil…
-
CLINICAL_TRIALS trial_result · 2013-10-31Clinical Trial Update: Methylphenidate for Treating Children With ADHD and Tourette Syndrome [NA]
A completed clinical trial evaluated the use of methylphenidate for treating children with attention-deficit/hyperactivity disorder and Tour…